Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
11.04
+0.06 (0.55%)
At close: Dec 5, 2025, 4:00 PM EST
11.32
+0.28 (2.54%)
After-hours: Dec 5, 2025, 5:11 PM EST
Contineum Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Contineum Therapeutics stock have an average target of 20, with a low estimate of 14 and a high estimate of 23. The average target predicts an increase of 81.16% from the current stock price of 11.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Contineum Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $16 → $14 | Buy | Maintains | $16 → $14 | +26.81% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $22 | Buy | Maintains | $25 → $22 | +99.28% | Nov 21, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $20 | Buy | Initiates | $20 | +81.16% | Sep 25, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $21 | Buy | Maintains | $20 → $21 | +90.22% | Aug 18, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $25 → $20 | Buy | Maintains | $25 → $20 | +81.16% | May 19, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.27
from -2.18
EPS Next Year
-2.62
from -2.27
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.25 | -2.00 | ||||
| Avg | -2.27 | -2.62 | ||||
| Low | -2.68 | -3.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.